BioInvent Financial Statements From 2010 to 2025
| BOVNF Stock | USD 3.29 0.00 0.00% |
Check BioInvent International financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioInvent International's main balance sheet or income statement drivers, such as , as well as many indicators such as . BioInvent financial statements analysis is a perfect complement when working with BioInvent International Valuation or Volatility modules.
BioInvent |
BioInvent International AB Company Current Valuation Analysis
BioInvent International's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current BioInvent International Current Valuation | 183.41 M |
Most of BioInvent International's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, BioInvent International AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, BioInvent International AB has a Current Valuation of 183.41 M. This is 98.72% lower than that of the Healthcare sector and 96.05% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 98.9% higher than that of the company.
BioInvent International Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining BioInvent International's current stock value. Our valuation model uses many indicators to compare BioInvent International value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioInvent International competition to find correlations between indicators driving BioInvent International's intrinsic value. More Info.BioInvent International AB is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioInvent International's earnings, one of the primary drivers of an investment's value.About BioInvent International Financial Statements
BioInvent International stakeholders use historical fundamental indicators, such as BioInvent International's revenue or net income, to determine how well the company is positioned to perform in the future. Although BioInvent International investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioInvent International's assets and liabilities are reflected in the revenues and expenses on BioInvent International's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioInvent International AB. Please read more on our technical analysis and fundamental analysis pages.
BioInvent International AB , a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. The Company was incorporated in 1996 and is based in Lund, Sweden. Bioinvent International operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 84 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in BioInvent Pink Sheet
BioInvent International financial ratios help investors to determine whether BioInvent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioInvent with respect to the benefits of owning BioInvent International security.